Registered number
08621268
Melon Pharma Limited
Filleted Accounts
30 September 2025

Melon Pharma Limited
Registered number: | 08621268
Balance Sheet
as at 30 September 2025
Notes |  |  | 2025 |  |  | 2024
£ | £
Fixed assets
Tangible assets | 3 |  |  | 3,880 |  |  | 2,970
Current assets
Debtors | 4 |  | 3,354 |  |  | 1,668
Cash at bank and in hand |  |  | 3,241 |  |  | 4,451
|  |  | 6,595 |  |  | 6,119
Creditors: amounts falling due within one year | 5 |  | (10,467) |  |  | (8,632)
Net current liabilities |  |  |  | (3,872) |  |  | (2,513)
Net assets |  |  |  | 8 |  |  | 457
Capital and reserves
Called up share capital |  |  |  | 2 |  |  | 2
Profit and loss account |  |  |  | 6 |  |  | 455
Shareholders' funds |  |  |  | 8 |  |  | 457
The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit in accordance with section 476 of the Act.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
D K Clarke, Esq
Director
Approved by the board on 18 December 2025

Melon Pharma Limited
Notes to the Accounts
for the year ended 30 September 2025
1 | Accounting policies
| Basis of preparation
| The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
| Turnover
| Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the rendering of services and is recognised by reference to the stage of completion of the contract, which is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
| Tangible fixed assets
| Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:
| Plant and machinery | over 5 years
| Debtors
| Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
| Creditors
| Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
| Taxation
| A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period.
2 | Employees | 2025 |  | 2024
Number | Number
| Average number of persons employed by the company | 1 |  | 1
3 | Tangible fixed assets
|  |  |  |  |  |  |  | Plant and machinery etc
£
| Cost
| At 1 October 2024 | 12,635
| Additions | 2,225
| At 30 September 2025 | 14,860
| Depreciation
| At 1 October 2024 | 9,665
| Charge for the year | 1,315
| At 30 September 2025 | 10,980
| Net book value
| At 30 September 2025 | 3,880
| At 30 September 2024 | 2,970
4 | Debtors | 2025 |  | 2024
£ | £
| Trade debtors | 712 |  | 1,668
| Other debtors | 2,642 |  | -
|  |  |  |  |  | 3,354 |  | 1,668
5 | Creditors: amounts falling due within one year | 2025 |  | 2024
£ | £
| Taxation and social security costs | 1,385 |  | 3,129
| Other creditors | 9,082 |  | 5,503
|  |  |  |  |  | 10,467 |  | 8,632
| Included in creditors is £5,937 (2024:£2,658) owing to the director. The loan is interest-free and there is no fixed date of repayment. The director has confirmed that the loan will only be repaid as and when cash flow permits.
6 | Controlling party
| The company is controlled by Mr Clarke and Ms Evans who own the entire share capital of the company.
7 | Other information
| Melon Pharma Limited is a private company limited by shares and incorporated in England. Its registered office is:
| 30 Cambridge Road,
| Hampton,
| England,
| TW12 2JL

Melon Pharma Limited 08621268 false 2024-10-01 2025-09-30 2025-09-30 VT Final Accounts April 2024 D K Clarke, Esq No description of principal activity 08621268 2023-10-01 2024-09-30 08621268 core:WithinOneYear 2024-09-30 08621268 core:ShareCapital 2024-09-30 08621268 core:RetainedEarningsAccumulatedLosses 2024-09-30 08621268 2024-10-01 2025-09-30 08621268 bus:PrivateLimitedCompanyLtd 2024-10-01 2025-09-30 08621268 bus:AuditExempt-NoAccountantsReport 2024-10-01 2025-09-30 08621268 bus:Director40 2024-10-01 2025-09-30 08621268 1 2024-10-01 2025-09-30 08621268 2 2024-10-01 2025-09-30 08621268 core:PlantMachinery 2024-10-01 2025-09-30 08621268 countries:England 2024-10-01 2025-09-30 08621268 bus:FRS102 2024-10-01 2025-09-30 08621268 bus:FilletedAccounts 2024-10-01 2025-09-30 08621268 2025-09-30 08621268 core:WithinOneYear 2025-09-30 08621268 core:ShareCapital 2025-09-30 08621268 core:RetainedEarningsAccumulatedLosses 2025-09-30 08621268 core:PlantMachinery 2025-09-30 08621268 2024-09-30 08621268 core:PlantMachinery 2024-09-30 iso4217:GBP xbrli:pure